Note 1: Segment Information continued Geographical areas of operation The Group operates predominantly in Australia, the United States, Germany, the United Kingdom, Switzerland and China. The rest of the Group’s operations are spread across many countries and are collectively disclosed as ‘Rest of World’. Inter-segment sales are carried out on an arm’s length basis and reflect current market prices. Geographic areas Australia US$m United States US$m Germany US$m UK US$m Switzerland US$m China US$m Rest of World US$m Total US$m 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 2023 2022 External operating revenue 1,045 1,022 6,563 5,124 869 781 717 596 488 281 779 745 2,849 2,013 13,310 10,562 PPE, right-of-use assets and intangible assets (excluding goodwill) 1,918 1,374 4,284 3,825 1,273 1,232 329 331 9,478 2,568 80 85 357 345 17,719 9,760 Note 2: Business Combinations The Group completed the acquisition of CSL Vifor on 9 August 2022 and paid $11,665m for 100% of CSL Vifor shares (includes shares acquired in the prior year ended 30 June 2022). The Group delisted Vifor Pharma Ltd from the Swiss Stock Exchange effective 23 December 2022. The acquisition has been accounted for as a business combination using the acquisition method of accounting in accordance with AASB 3 ‘Business Combinations’ and consequently the CSL Vifor assets acquired, and liabilities assumed, have been recorded at fair value, with any excess of the purchase price over the fair value of the identifiable assets and liabilities being recognised as goodwill. The purchase price allocation was finalised during the year ended 30 June 2023. The purchase consideration, and fair values of the net assets acquired and goodwill at the date of acquisition are as follows: Fair value as at the date of acquisition US$m Cash and cash equivalents 743 Receivables and contract assets (note a) 527 Inventories (note b) 459 Current tax assets 7 Property, plant and equipment (note c) 179 Right-of-use assets 40 Intangible assets excluding goodwill (note e) 6,706 Deferred tax assets (note i) 101 Other financial assets (note d) 525 Trade and other payables (488) Interest bearing liabilities and borrowings (630) Current tax liabilities (59) Provisions (note f) (434) Deferred tax liabilities (note i) (759) Net identifiable assets acquired 6,917 Less: Non-controlling interests (NCI) (note g) (2,144) Add: Goodwill (note h) 6,892 Fair value of net assets acquired 11,665 Consideration paid in the prior year ended 30 June 2022 388 Consideration paid in the year ended 30 June 2023 11,277 Total purchase consideration 11,665 CSL Limited Annual Report 2022/23 121
RkJQdWJsaXNoZXIy MjE2NDg3